Ashley Gallagher

New Jersey, New York

Associate Editor at Pharmacy Times

Music Journalist and Photographer | she/her | @disruptedpress | business inquiry: [email protected]

Articles

FDA Approves Dupilumab for Treatment of Bullous Pemphigoid

1 week ago | drugtopics.com | Ashley Gallagher

The FDA approved dupilumab (Dupixent) for the treatment of bullous pemphigoid in adults.1 “Until now, treating bullous pemphigoid was very challenging for elderly patients struggling with the debilitating impact of blisters and lesions and potentially comorbid conditions,” Alyssa Johnsen, MD, PhD, global therapeutic area head of immunology and oncology development at Sanofi, said in a news release.1 “By addressing 2 central drivers of the underlying type 2 inflammation that contributes to...
Cannabis Use Linked With Increased Risk of Major Adverse Cardiovascular Events

1 week ago | drugtopics.com | Ashley Gallagher

In a new systematic review and meta-analysis, investigators found a positive association between cannabis use and major adverse cardiovascular events (MACE), raising awareness about the potential risks to cardiovascular health for cannabis users.1In an editorial published in Heart, the authors write that there has been frequent cannabis use increasing in several countries as many believe it is a safe and effective way to relieve pain despite evidence of health risks.
FDA Approves Nitisinone for Treatment of Alkaptonuria

1 week ago | drugtopics.com | Ashley Gallagher

The FDA approved nitisinone (Harliku) for the reduction of urine homogentisic acid (HGA) in patients with alkaptonuria (AKU). Nitisinone is the first and only FDA-approved treatment for AKU, a rare genetic metabolic disorder that causes buildup of HGA and can lead to osteoarthritis, ochronosis, and complications in the kidneys and heart. The medication is expected to launch in July 2025.1“The approval of Harliku is an important advance for the AKU community.
Dapagliflozin Improves Health Outcomes for Adolescents With Type 1 Diabetes

1 week ago | drugtopics.com | Ashley Gallagher

In a clinical trial (NCT04333823), investigators found that combination therapy with insulin and investigational dapagliflozin could reduce chronic kidney disease and improve outcomes for adolescents with type 1 diabetes (T1D).
Gut Microbiome Composition Could Be Linked With Risk of Cognitive Impairment

1 week ago | drugtopics.com | Ashley Gallagher

Investigators found that the composition of the gut microbiome could potentially be linked with the risk of cognitive impairment in adults. They believe the role could show how biology and social determinants play in brain health.
Mark Cuban Cost Plus Drugs, 9amHealth Collaborate to Make Obesity Medications Affordable

1 week ago | drugtopics.com | Ashley Gallagher

Mark Cuban Cost Plus Drug Company announced a collaboration with 9amHealth that aims to make obesity medication more affordable and accessible to employers nationwide.1 "We are thrilled to collaborate with 9amHealth in our mission to make prescription drugs more affordable for consumers," Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company, said in a news release.1 "At Cost Plus Drugs, our commitment to transparent drug pricing has always been unwavering, and with clinical leaders in...
Sleep Habits Could Influence Risk of Type 2 Diabetes

1 week ago | drugtopics.com | Ashley Gallagher

Changed brain functional network connectivity as well as sleep habits can influence the risk of type 2 diabetes (T2D), according to results of a study published in Diabetology and Metabolic Syndrome. The authors stated that the “critical function that brain networks play in modulating the link between sleep patterns and the prevalence of T2DM.”1T2D and sleep frequently coexist, according to authors of a study in Cureus.
Eli Lilly Adds Highest Doses of Zepbound to Online Pharmacy Platform

1 week ago | drugtopics.com | Ashley Gallagher

Eli Lilly announced that the highest doses of tirzepatide (Zepbound)—12.5 mg and 15 mg—will be available in single-dose vials for $499 per month through LillyDirect’s Self-Pay Pharmacy Solutions and the Zepbound Self-Pay Journey Program.
Dupilumab Shows Superiority Over Omalizumab for Chronic Rhinosinusitis

1 week ago | drugtopics.com | Ashley Gallagher

In a phase 4 trial, dupilumab (Dupixent) showed superiority on all primary and secondary end points compared with omalizumab (Xolair) for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma.
Overdose Deaths Begin to Sustain Decline After Decades Long Increase

1 week ago | drugtopics.com | Ashley Gallagher

Investigators find a new wave of sustained declines in drug overdose deaths in 2023 after nearly 2 decades of increases. According to results of a study published in JAMA Network Open, the decline is encouraging, but there are still disparities that will require more targeted interventions and understanding of underlying drivers.1According to the National Institute on Drug Abuse, over 105,000 people in the US died from a drug-related overdose in 2023, which did decline from 2021 and 2022.